RT Journal Article
SR Electronic
T1 Extended dual antiplatelet therapy following percutaneous coronary intervention in clinically important patient subgroups: a systematic review and meta-analysis
JF CMAJ Open
JO CMAJ
FD Canadian Medical Association
SP E118
OP E130
DO 10.9778/cmajo.20210119
VO 11
IS 1
A1 Jesse Elliott
A1 Shannon E. Kelly
A1 Zemin Bai
A1 Becky Skidmore
A1 Michel Boucher
A1 Derek So
A1 George A. Wells
YR 2023
UL http://www.cmajopen.ca/content/11/1/E118.abstract
AB Background: Dual antiplatelet therapy (DAPT) is routinely given to patients after percutaneous coronary intervention (PCI) with stenting; however, optimal duration remains uncertain in some situations. We assessed the benefits and harms of extending DAPT beyond 1 year after PCI in clinically important patient subgroups.Methods: We conducted a systematic review and meta-analysis. We searched electronic databases (Embase, MEDLINE, PubMed, Cochrane Library) and grey literature (from inception to Nov. 5, 2021) and included randomized controlled trials (RCTs) of extended DAPT (> 12 mo) compared with DAPT for 6–12 months following PCI with stenting. The primary outcome was death (all cause, cardiovascular, noncardiovascular); secondary outcomes included major adverse cardiovascular and cerebrovascular events, myocardial infarction (MI), stroke, stent thrombosis and bleeding. Subgroups were based on prespecified patient characteristics (prior MI, acute coronary syndrome [ACS], diabetes mellitus, age, smoking status). Data were analyzed by random-effects pairwise meta-analysis.Results: We identified 9 RCTs that provided subgroup data. We found that extended DAPT reduced the risk of MI and stent thrombosis but increased the risk of bleeding, compared with standard DAPT, with no difference in the risk of all-cause death (relative risk [RR] 1.07, 95% confidence interval [CI] 0.80–1.42) or cardiovascular death (RR 0.98, 95% CI 0.74–1.30). We found that patients with a prior MI, with ACS at presentation, without diabetes or aged younger than 75 years may derive the most benefit from extended DAPT. Among patients who received extended DAPT, the risk of all-cause death was significantly increased among those with no prior MI (RR 1.64, 95% CI 1.08–2.24), whereas there was no significant difference in the risk of all-cause death between standard and extended DAPT for patients with ACS (RR 1.20, 95% CI 0.51–2.83), with diabetes (RR 1.27, 95% CI 0.86–1.89), aged older than 75 years (RR 1.32, 95% CI 0.39–4.54) or who smoked (RR 0.90, 95% CI 0.42–1.92). Similar results were found for cardiovascular death, where data were available.Interpretation: Patients with a previous MI with ACS at presentation, without diabetes, or aged younger than 75 years may derive the most benefit from extended DAPT. These findings support the need for careful selection of patients who may benefit most from extended DAPT. Study registration: PROSPERO no. CRD42018082587